Safety and Efficacy of Azelaic Acid Foam, 15% in Papulopustular Rosacea

Inclusion Criteria: * Signed written informed consent * Diagnosis of papulopustular rosacea (IGA score of moderate or severe) with a minimum of 12 and maximum of 50 inflammatory lesions (papules and/or pustules) and persistent erythema with or without telangiectasia * Free of any clinically significant disease which could interfere with the study * Willingness to follow all study procedures * Male or female patient at least 18 years of age Exclusion Criteria: * Subjects known to be non-responders to azelaic acid * Presence of dermatoses that might interfere with the rosacea diagnosis or the evaluation of treatment results * Ocular rosacea, phymatous rosacea * Any condition or therapy that in the opinion of the investigator may pose a risk to the patient of interfere with any evaluation in the study * Facial laser surgery in the 6 weeks prior to the study * Topical or systemic use of prescription or non-prescription medications to treat rosacea * Use of any agent other than the investigational drugs to treat rosacea during the study * Expected use or change in dose in the 90 days prior to the study of beta-blockers, vasodilators, NSAIDs, hormonal treatment or drugs causing acneiform eruptions * Known hypersensitivity to any ingredients of the investigational product formulation * Alcohol or drug abuse * Incapability of giving fully informed consent * Subject is dependent person, i.e., a relative/family member of the investigator and/or is a member of the investigator's staff * Participation in another clinical research study within the last 4 weeks before randomization in this study